Abliva Logo

Abliva

ISIN: SE0002575340 | Ticker: ABLI | LEI: 5493005YV22OTMUHZ183
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About Abliva

Company Description

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly.

The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022.

Year founded

2000

Served area

Worldwide

Headquarters

Scheeletorget 1, 22381 Lund – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 98,957,000.00 58,918,000.00 183,829,000.00
Noncurrent Assets N/A 35,800,000.00 34,664,000.00 34,013,000.00
Property Plant And Equipment N/A 384,000.00 60,000.00 908,000.00
Other Intangible Assets N/A 1,344,000.00 1,210,000.00 1,075,000.00
Investments In Associates Accounted For Using Equity Method N/A 13,101,000.00 13,101,000.00 13,101,000.00
Current Assets N/A 63,157,000.00 24,254,000.00 149,816,000.00
Other Current Receivables N/A 928,000.00 912,000.00 849,000.00
Cash and cash equivalents 58,319,000.00 61,643,000.00 22,339,000.00 66,392,000.00
Current Investments N/A N/A 0.00 78,949,000.00
Equity And Liabilities N/A 98,957,000.00 58,918,000.00 183,828,000.00
Equity 76,089,000.00 88,656,000.00 41,528,000.00 164,287,000.00
Issued Capital N/A 14,817,000.00 20,150,000.00 52,815,000.00
Retained Earnings N/A -586,802,000.00 -709,879,000.00 -794,582,000.00
Other Reserves N/A 616,000.00 688,000.00 833,000.00
Additional Paidin Capital N/A 660,025,000.00 730,560,000.00 905,221,000.00
Equity Attributable To Owners Of Parent N/A 88,656,000.00 41,519,000.00 164,287,000.00
Noncontrolling Interests N/A 0.00 9,000.00 0.00
Liabilities N/A 10,301,000.00 17,390,000.00 19,541,000.00
Noncurrent Liabilities N/A 92,000.00 0.00 534,000.00
Other Noncurrent Liabilities N/A 92,000.00 0.00 534,000.00
Current Liabilities N/A 10,209,000.00 17,390,000.00 19,007,000.00
Trade And Other Current Payables To Trade Suppliers N/A 4,201,000.00 9,616,000.00 4,860,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A 7,497,000.00 13,599,000.00
Other Current Liabilities N/A 675,000.00 277,000.00 548,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 216,000.00 151,000.00 31,000.00
Other Income 1,648,000.00 0.00 1,716,000.00
Employee Benefits Expense 13,305,000.00 16,844,000.00 14,028,000.00
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 2,558,000.00 2,764,000.00 2,610,000.00
Other Expense By Nature 0.00 330,000.00 0.00
Profit Loss From Operating Activities -60,071,000.00 -123,482,000.00 -83,190,000.00
Finance Income N/A 0.00 392,000.00
Finance Costs 30,000.00 12,000.00 2,764,000.00
Profit Loss Before Tax -59,994,000.00 -123,494,000.00 -85,264,000.00
Income Tax Expense Continuing Operations 0.00 4,000.00 0.00
Profit (loss) -59,994,000.00 -123,498,000.00 -85,264,000.00
Profit Loss Attributable To Owners Of Parent -59,989,000.00 -123,492,000.00 -85,262,000.00
Profit Loss Attributable To Noncontrolling Interests -5,000.00 -6,000.00 -2,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -59,994,000.00 -123,498,000.00 -85,264,000.00
Adjustments For Depreciation And Amortisation Expense N/A 2,558,000.00 2,660,000.00 2,610,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 0.00 -7,000.00 192,000.00
Adjustments For Sharebased Payments N/A 0.00 415,000.00 551,000.00
Adjustments For Undistributed Profits Of Associates N/A -107,000.00 0.00 -298,000.00
Interest Paid Classified As Operating Activities N/A 30,000.00 12,000.00 25,000.00
Interest Received Classified As Operating Activities N/A N/A 0.00 392,000.00
Cash Flows From Used In Operating Activities N/A -67,558,000.00 -114,075,000.00 -159,560,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 0.00 65,000.00 23,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 1,407,000.00 1,024,000.00 882,000.00
Cash Flows From Used In Investing Activities N/A -1,407,000.00 -1,089,000.00 -905,000.00
Proceeds From Issuing Shares N/A 72,564,000.00 75,868,000.00 180,364,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 269,000.00 92,000.00 170,000.00
Cash Flows From Used In Financing Activities N/A 72,295,000.00 75,792,000.00 204,417,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 3,330,000.00 -39,372,000.00 43,952,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -6,000.00 68,000.00 101,000.00
Cash and cash equivalents 58,319,000.00 61,643,000.00 22,339,000.00 66,392,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE / ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
13.07.23 David Laskow-Pooley Other Buy SEK 11,664.58
13.07.23 David Laskow-Pooley Other Buy SEK 8,151.00
13.07.23 David Laskow-Pooley Other Buy SEK 7,807.86
13.07.23 David Laskow-Pooley Other Buy SEK 3,267.20
13.07.23 David Laskow-Pooley Other Buy SEK 2,588.47
13.07.23 David Laskow-Pooley Other Buy SEK 2,479.40
13.07.23 David Laskow-Pooley Other Buy SEK 2,474.86
13.07.23 David Laskow-Pooley Other Buy SEK 2,469.50
13.07.23 David Laskow-Pooley Other Buy SEK 2,456.96
13.07.23 David Laskow-Pooley Other Buy SEK 2,451.85

Capital markets information

ISIN

SE0002575340

LEI

5493005YV22OTMUHZ183

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.